Support Line: 0300 373 8500
This is an early phase study, looking to find out more about a new type of targeted treatment called CCS1477 or inobrodib.
This drug targets proteins called histone acetyltransferases (HATs), which control the way some cells develop. The drug stops HATs working, which stops cancer cells from growing. The study aims to measure the safety of the drug and understand best doses, before expanding into combining it with other therapies.
• Confirmed WM diagnosis
• You must have previously received standard treatment
